Two COVID shots effective against India variant: English health body
Reuters
Published May 22, 2021 05:33PM ET
Updated May 23, 2021 08:21AM ET
LONDON (Reuters) - A double dose of COVID-19 vaccines is almost as effective against the fast-spreading variant of the coronavirus first identified in India as it is against Britain's dominant strain, English health officials said on Saturday.
Britain's health minister said the data was groundbreaking and he was increasingly hopeful that the government would be able to lift more COVID restrictions next month.
A study by Public Health England found the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 variant two weeks after the second dose.
That compared with 93% effectiveness against the B.1.1.7 "Kent" strain which is Britain's dominant COVID variant.
Two doses of the AstraZeneca (NASDAQ:AZN) vaccine were 60% effective against symptomatic disease from the Indian variant compared with 66% effectiveness against the Kent variant, PHE said.
"I'm increasingly confident that we're on track for the roadmap, because this data shows that the vaccine, after two doses, works just as effectively (against the Indian variant)," Health Secretary Matt Hancock told broadcasters.
Under the government's plans, a lifting of remaining coronavirus restrictions is due to take place from June 21.
Britain has rushed out Europe's fastest vaccination programme so far but it has faced a new challenge from the spread of the variant first found in India.
Data published on Saturday showed new COVID cases reported in Britain rose by 10.5% in the seven days to May 22 although it remained a fraction of levels seen earlier this year.
Prime Minister Boris Johnson this month ordered an acceleration of remaining second doses to the over 50s and people who are clinically vulnerable.
PHE said a first dose of both vaccines was 33% effective against symptomatic disease from B.1.617.2 after three weeks, lower than its 50% effectiveness against B.1.1.7.
Hancock said that showed that getting both doses of the vaccine was "absolutely vital."
Concern about rising cases in Britain of the variant first found in India prompted Germany to say on Friday that anyone entering the country from the United Kingdom would have to quarantine for two weeks on arrival.
Get The News You Want
Also on Friday, the head of Germany's public health institute said existing COVID-19 vaccines might be less effective against the B.1.617.2 variant.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.